By Straumann staff

Straumann is pleased to introduce Emdogain 015, a versatile and cost-effective way to treat patients with periodontal disease. Emdogain 015 is the same effective product clinicians have relied on for treatment of more than 1 million patients, now in a new, convenient package size of five syringes, each filled with 0.15 ml of product. Emdogain 015 gives clinicians an ideal and more cost-effective solution for the treatment of small periodontal defects. Straumann Emdogain is a protein-based gel designed to promote predictable regeneration of lost periodontal hard and soft tissue, helping to save and stabilize teeth.

The addition of Emdogain 015 to Straumann’s regenerative treatment portfolio gives clinicians the flexibility to select the right amount of Emdogain for their patients. When added into the periodontal treatment plan, Emdogain can provide an excellent result with less pain and discomfort compared to connective tissue graft (CTG), while improving the potential for patients to keep their natural teeth.

“Using Emdogain, I’ve seen positive outcomes for my patients, however, there have been times when I wanted to use Emdogain in conjunction with periodontal surgery but couldn’t justify the excess material that would go to waste when treating smaller defects,” said Jennifer Hirsch Doobrow, DMD. “Now, with Emdogain 015, I can provide the power of regenerative therapy to more patients because the size of the defect is no longer an issue.”

According to the Centers of Disease Control and Prevention (CDC), about half of the U.S. population is affected by periodontal disease, which if left untreated, may lead to tooth loss. Periodontitis treatment involves controlling the causative bacteria and inflammation, as well as subsequent regeneration of the lost periodontal hard and soft tissue in order to regain tooth attachment.

Straumann Emdogain supports the predictable regeneration of the lost periodontal hard and soft tissue caused by periodontitis, helping to save and preserve the tooth. Scientifically supported in more than 400 publications, Emdogain is designed to help clinicians produce long-lasting results that will in turn help them in developing a successful practice through satisfied patients.

“Emdogain has had strong long-term results, and we believe that every patient – whether the clinical situation is a small defect or a large grafting procedure – should have the opportunity to experience these benefits. This is why we created Emdogain 015,” said Andy Molnar, executive vice president, Straumann North America. “With longer life expectancies, today’s patients want more options when it comes to their oral health. We are committed to giving clinicians innovative and effective products to help them provide the best possible care for their patients.”

Straumann — a global leader in implant dentistry offering surgical, restorative, regenerative and digital solutions for the dental and lab business — is a pioneer of innovative technologies. To learn more about Straumann, visit www.straumann.us.

References available upon request from the publisher.